AR-42 is a novel HDAC inhibitor with an IC50 of 0.61 ¦ÌM for acute lymphoblastic leukemia (697) cell lines.In chronic lymphocytic leukemia (CLL) cells, the 48-hr LC50 of AR-42 is 0.76 ¦ÌM. AR-42 produces dose- and time-dependent acetylation both of histones and tubulin, and induces caspase-dependent apoptosis that is not reduced in the presence of stromal cells. AR-42 significantly reduced leukocyte counts and/or prolonged survival in three separate mouse models of B-cell malignancy without evidence of toxicity. AR-42 has in vitro and in vivo efficacy at tolerable doses. In additon, AR-42 promoted hyperacetylation of H3, H4, and alpha-tubulin, and up-regulation of p21. Down-regulation of Kit occurred after AR-42 treatment via inhibition of Kit transcription.

June 21, 2017

prudect name : AR-42 is a novel HDAC inhibitor with an IC50 of 0.61 ¦ÌM for acute lymphoblastic leukemia (697) cell lines.In chronic lymphocytic leukemia (CLL) cells, the 48-hr LC50 of AR-42 is 0.76 ¦ÌM. AR-42 produces dose- and time-dependent acetylation both of histones and tubulin, and induces caspase-dependent apoptosis that is not reduced in the presence of stromal cells. AR-42 significantly reduced leukocyte counts and/or prolonged survival in three separate mouse models of B-cell malignancy without evidence of toxicity. AR-42 has in vitro and in vivo efficacy at tolerable doses. In additon, AR-42 promoted hyperacetylation of H3, H4, and alpha-tubulin, and up-regulation of p21. Down-regulation of Kit occurred after AR-42 treatment via inhibition of Kit transcription.
AR-42

Synonyms: HDAC-42,OSU-HDAC42CAS NO: 935881-37-1Molecular Formula: C₁₈H₂₀N₂O₃Molecular Weight: 312.36Purity: 98% minSolubility: Storage: -20¡æ

53123-88-9 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18497531